Dr Giovanni Randon speaks to ecancer about his ARMANI phase III trial.

This study evaluated the efficacy of switch maintenance therapy in patients with HER2-negative advanced gastric or gastroesophageal junction cancer who did not progress after 3 months of oxaliplatin-based chemotherapy.

Patients were randomised to receive either ramucirumab plus paclitaxel or continued CAPOX/FOLFOX followed by fluoropyrimidine monotherapy.

The primary endpoint was progression-free survival (PFS).

Results showed a significant improvement in median PFS and overall survival (OS) with ramucirumab plus paclitaxel compared to the CAPOX/FOLFOX group.

The benefits were consistent across various clinical and molecular subgroups, including those with low PD-L1 expression.